09Oct
Caremark Round II: Beware Red Flags in Drug Development
On October 1, 2019, the Delaware Court of Chancery applied the Delaware Supreme Court’s recent decision on Caremark board oversight claims in the context of operating in a highly regulated industry to allow derivative claims to proceed against the...
By:
Goodwin
Related
Last week, the National Labor Relations Board (“Board”) held that employer policies that prohibit ...
Read More >
But it depends on what your definition of "complete" is. The Equal Employment Opportunity Commissio...
Read More >
You have undoubtedly read about the continuing popularity of special purpose acquisition companies (...
Read More >
The judgment provides useful jurisdictional clarifications for deals involving joint ventures (JVs) ...
Read More >
Pittsburgh-based PNC Financial Services Group has reached a deal worth some $11.6 billion to buy the...
Read More >
We are excited to bring the healthcare compliance sessions and updates to you as an interactive, onl...
Read More >